Endocrinology Medical News about Dyslipidemias Pitavastatin

Your Unread Messages

See All

Tracy Hampton, PhD

Clinical Trial Watch

Whole-Brain Radiation Affects Learning and Memory in Brain Cancer Patients

Roberta Buell, MBA
Congress Proposes SGR Fix

Dorothy J. Schirf, MD

Technology Advances

Magnetic Nanosensor Prepped for Early Cancer Detection

Sara Hartley

Technology Advances

A New Strategy for Protecting Ovaries in Young Cancer Patients

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

3. Rapid correction of low vitamin D status in nursing home residents

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals
Vascular Health and Risk Management, 11/03/09

Saito S – Pitavastatin is a potent HMG–CoA reductase inhibitor and efficient hepatocyte low–density lipoprotein cholesterol (LDL–C) receptor inducer, producing robust reduction of the serum LDL–C levels, even at a low dose. Pitavastatin and its lactone form are minimally metabolized by CYP enzymes, and are therefore associated with minimal drug–drug interactions (DDIs). Pitavastatin 2 to 4 mg has potent LDL–C–reducing activity, equivalent to that of atorvastatin 10 to 20 mg; several clinical trials have revealed consistently superior high–density lipoprotein cholesterol (HDL–C) elevating activity of pitavastatin than that of atorvastatin. Pitavastatin–induced HDL–C elevation has been shown to be sustained, even incremental, in long–term clinical trials. Pitavastatin was as well–tolerated as atorvastatin or simvastatin in double–blind randomized clinical trials. Two–year long–term safety and effectiveness of pitavastain has been confirmed in a large–scale, prospective post–marketing surveillance. In addition to control of LDL–C, adequate control of triglyceride (TG) and HDL–C, hypertension and hyperglycemia is also necessary in metabolic syndrome patients.

<< Previous
Dysregulation of glucose, insulin, triglyceride, blood pressure,...

Next >>
Prospective, randomized, controlled trial of parathyroidectomy...